The FDA and EPA, under the Trump administration, are phasing out animal testing, opting for innovative alternatives. This decision has drawn applause from animal rights organizations and ethical advocates alike, marking a significant shift in policy across federal agencies.
Trump Administration Receives Bipartisan Support for Ending Animal Testing
Trump Administration Receives Bipartisan Support for Ending Animal Testing
Major reforms announced by the FDA and EPA to eliminate animal testing garner praise from diverse political factions and advocacy groups.
The Trump administration is garnering unexpected bipartisan support for its recent announcement aimed at phasing out animal testing within federal agencies, particularly the Food and Drug Administration (FDA) and the Environmental Protection Agency (EPA).
On Thursday, the FDA disclosed plans to gradually remove animal testing requirements for various therapies and drug treatments. Instead, the agency will adopt advanced technologies, such as organ-on-a-chip systems that accurately replicate human biological responses.
The announcement was met with immediate praise from PETA, one of the leading animal rights organizations globally. Kathy Guillermo, PETA's senior vice president, stated, “PETA applauds the FDA’s decision to stop harming animals and adopt human-relevant testing strategies for evaluating antibody therapies. This is a significant step toward fulfilling the agency’s commitment to replace the use of animals.”
Guillermo further urged the administration to extend its reforms by halting ineffective primate testing at federally funded research centers while advocating for the FDA to fully embrace modern scientific approaches.
In addition, the EPA has started to diminish its reliance on animal testing, making the current administration the first in U.S. history to implement coordinated changes across multiple federal agencies. This shift towards a more ethical and innovative testing paradigm is being hailed as a landmark move in the realms of scientific ethics and policy, attracting support from groups typically at odds with Trump’s agenda.
